Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

recombinant fowlpox GM-CSF vaccine adjuvant

A cancer vaccine adjuvant consisting of a recombinant fowlpox virus encoding human granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF binds to specific cell surface receptors on various immuno-hematopoietic cell types, enhancing their proliferation and differentiation and stimulating macrophage and dendritic cell functions in antigen presentation and antitumor cell-mediated immunity. Administration of recombinant fowlpox GM-CSF vaccine adjuvant may induce an immune response against tumor cells. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:fowlpox-GM-CSF
fowlpox-sargramostim
rf-sargramostim
Abbreviation:rf-GM-CSF
NSC code:707299
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search